Jade Biosciences, Inc.

NASDAQ:JBIO

Biotechnology

Healthcare
$15.49 -1.25%

-$0.21 today

Market cap
$1.07B
Beta
1.45
P/E (TTM)
-7.4
EPS (TTM)
-$2.24
52W Low $6.67High $28.00

Volume 0.79M

Average 0.83M

JBIO Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Jade Biosciences, Inc.NASDAQ: JBIO

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 57.78M shares rose 6876.7% year over year, ahead of the +3008.4% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 17.2% from the prior quarter. Over 3 fiscal years it compounded at +255.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +6876.7% holds above the trailing-twelve-month pace of +3008.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
57.78M+17.2% QoQ
Last fiscal yearDec 2025
31.36M+3740.1% YoY
LTMMar 2026
43.78M+3008.4% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6876.7%——
1 year+3740.1%——
3-year CAGR+255.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
31.36M USD
Year-over-year change
+3740.1%
4-year CAGR
+159.0%

Weighted Avg Shares (Diluted) vs competitors

How JBIO compares with its peers on the latest reported figures

  • JBIO's LTM Mar 2026 weighted avg shares (diluted) of 43.78M shares is the 6th highest of the 9 companies compared; the peer median is 57.08M shares.
  • Its year-over-year change of +3008.4% is the highest of 8, against a peer median of +18.4%.
  • Over three fiscal years its annual growth of +255.3% compares with a peer median of +30.0%.
JBIO Competitors Peer median
Weighted Avg Shares (Diluted) for JBIO and competitors
Company Period LTM YoY 3-year CAGR
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 202685.54M +45.8%+78.9%
VERAVera Therapeutics, Inc.LTM Jun 202667.85M +14.4%+34.2%
MLTXMoonLake ImmunotherapeuticsLTM Mar 202665.6M +4.1%+30.0%
KYTXKyverna Therapeutics, Inc.LTM Mar 202648.56M +12.5%+19.7%
JBIOJade Biosciences, Inc.LTM Mar 202643.78M +3008.4%+255.3%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 202630.55M +18.4%+3.3%
DWTXDogwood Therapeutics, Inc.LTM Mar 202612.86M +976.2%+164.8%
TRAXFirst Tracks Biotherapeutics IncFY20250 ——
Peer median (excluding JBIO) 57.08M+18.4%+30.0%

Competitors are the stored peer set for JBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue15K68K96K282K0
Gross Profit(15K)(68K)(96K)(282K)0
Gross Margin—————
Research & Development14.99M38.62M64.22M53.19M93.12M
Selling, General & Admin8.02M14.55M17.09M21.13M20.42M
Operating Expenses23.01M53.17M81.31M74.31M113.54M
Depreciation & Amortization15K68K96K282K26K
EBITDA(22.95M)(51.42M)(75.37M)(69.29M)(127.33M)
EBITDA Margin—————
Operating Income(23.02M)(53.24M)(81.41M)(74.6M)(113.54M)
Operating Margin—————
Interest Income65K1.83M5.95M5.04M7.78M
Interest Expense00000
Other Income / Expenses62K1.75M5.94M5.02M(13.81M)
Income Before Tax(22.96M)(51.49M)(75.47M)(69.57M)(127.35M)
Pre-Tax Margin—————
Income Tax Expense3K25K56K55K58K
Net Income(22.96M)(51.51M)(75.52M)(69.63M)(127.41M)
Net Margin—————
EPS (Basic)(32.96)(73.67)(100.38)(85.26)(4.06)
EPS (Diluted)(32.96)(73.67)(100.38)(85.26)(4.06)
Weighted Avg Shares697.44K699.2K752.33K816.63K31.36M
Weighted Avg Shares (Diluted)697.44K699.2K752.33K816.63K31.36M

Jade Biosciences, Inc.

NASDAQ:JBIO

Intrinsic Alpha fair value

Locked

Current Price

$15.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.